Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180
Dementia01:30

Dementia

111
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
111

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nicotinamide Riboside Enhances Mitochondrial Bioenergetics and Dopaminergic Signaling Independent of Neuron Survival in a Double-Hit Parkinson's Model.

Research square·2026
Same author

Post-meal loss of consciousness in an adult patient with carbamoyl phosphate synthetase 1 deficiency and two newly identified heterozygous variants: a case report.

BMC neurology·2026
Same author

Endovascular treatment versus standard medical management in primary M3 or M4 occlusion stroke in clinical practice: the oriental-MeVO registry.

BMC neurology·2026
Same author

Sex-Dependent Effects of Glutamatergic Disruption on Dopaminergic Neuron Subtype Vulnerable in Parkinson's Disease.

bioRxiv : the preprint server for biology·2026
Same author

Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder.

Signal transduction and targeted therapy·2026
Same author

Associations between sleep disturbance and cerebrospinal fluid Aβ, and shared proteomic signatures in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Related Experiment Video

Updated: Jun 25, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

148

Progress on early diagnosing Alzheimer's disease.

Yixin Chen1, Murad Al-Nusaif1, Song Li1

  • 1Liaoning Provincial Key Laboratory for Research on the Pathogenic Mechanisms of Neurological Diseases, The First Affiliated Hospital of Dalian Medical University, Dalian, 116021, China.

Frontiers of Medicine
|May 20, 2024
PubMed
Summary

Early detection of Alzheimer's disease (AD) is vital. New research highlights non-cognitive changes and biofluid biomarkers in preclinical AD, offering hope for improved diagnostic techniques.

Keywords:
Alzheimer’s diseasebiomarkersearly diagnosisnon-cognitive symptoms

More Related Videos

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.0K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K

Related Experiment Videos

Last Updated: Jun 25, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

148
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.0K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Gerontology

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder impacting cognitive and non-cognitive functions.
  • Current diagnostic methods for AD are often invasive, expensive, and lack sensitivity for early detection.
  • Non-cognitive symptoms like sleep disturbances and behavioral changes appear before significant cognitive decline in preclinical AD.

Purpose of the Study:

  • To review recent advances in identifying non-cognitive manifestations and biofluid biomarkers for early Alzheimer's disease detection.
  • To highlight the need for sensitive and specific diagnostic techniques for the preclinical stages of AD.
  • To explore the potential of predictive systems for forecasting AD onset and progression.

Main Methods:

  • Literature review of recent research on Alzheimer's disease.
  • Focus on non-cognitive symptoms and biofluid biomarkers in preclinical AD.
  • Analysis of diagnostic challenges and future directions for early AD detection.

Main Results:

  • Non-cognitive changes are observable in preclinical Alzheimer's disease.
  • Several biofluid biomarkers have been identified as potential early indicators of AD.
  • Existing diagnostic tools are insufficient for detecting early-stage AD.

Conclusions:

  • There is a critical need for novel, sensitive, and specific diagnostic tools for preclinical Alzheimer's disease.
  • Non-cognitive symptoms and novel biofluid biomarkers show promise for early AD detection.
  • Developing predictive systems could significantly improve AD management and treatment outcomes.